Try our Advanced Search for more refined results
Life Sciences - March, 2012
255 articles
- Prometheus To Wreak Vast Patent Turmoil, Experts Say
- Baker & McKenzie Snags Expert IP Litigator From Torys
- Ex-Novartis Consultant's FCA Retaliation Suit Stays Alive
- Ista Investor Sues To Block $500M Bausch & Lomb Deal
- FDA User Fee Bill Eyes Drug Shortages, New Antibiotics
- Investor Class Certified On Claims Pfizer Masked Drug Risks
- Judge Says Apotex Generic Doesn't Infringe Cephalon Patent
- AstraZeneca's Seroquel XR Ruled Valid And Infringed
- Case Study: Hermelin V. KV Pharmaceutical
- FDA Panel Says Obesity Drugs Need Tougher Clinical Trials
- Pfizer Urges JPML To Combine Zoloft Cases In NY
- Lambda Says Gay Juror's Dismissal Illegal In GSK-Abbott Row
- FDA To Give Drugmakers Leeway On ACA Reporting Deadline
- Sens. Warn Colleagues Not To Derail FDA User Fee Bill
- Volcano Owes Subsidiary's Shareholders $27M, Suit Says
- Novartis Settles Kentucky Drug-Pricing Claims For $3M
- Judge Denies AstraZeneca's Seroquel Challenge But Blasts FDA
- Horizon Tries To Thwart Par's Plans For Arthritis Generic
- Roche Bumps Illumina Cash Offer Up To $6.5B
- New Safety Worries Spark FDA Scrutiny Of Metal Hip Implants
- Searching For Patent Drafting Pointers In Prometheus
- States' Medicaid Coercion Argument Sways Some Justices
- FDA Could Make Generics Liable Amid Push To Undo Mensing
- Justices Divided On Power To Scrap Entire Health Care Law
- Judge Again Tosses Abbott Patent For Inequitable Conduct
- AstraZeneca Sues FDA As Firms Debut Generic Seroquel
- Cypress Pays $2.8M To Settle FCA Suit Over Unapproved Drugs
- Merchant & Gould Brings Biotech Patent Pair To Denver
- Fed. Circ. Orders Arbitration In Gene Test Royalty Row
- FDA Revises Celexa Warnings Over Heart Disorder Risk
- Covidien Doesn't Infringe Surgical Seal Patent, Judge Says
- Ratting Out The Competition: New DOJ Strategies
- Must-Have Performance Metrics For Law Departments
- GE, Cardinal Accused Of Manipulating Cardiac Imaging Market
- High Court's Take On Health Market Key To ACA Decision
- Bipartisan Senate Bill Aims To Hasten Key Drug Approvals
- Cetero Gets Nod To Borrow $2.4M To Fund Ch. 11 Sale
- FDA Sheds Light On Medical Device Risk Reviews
- Lawmakers Vow Health Law Repeal If High Court Lets It Stand
- Biotronik Wants $100M Suit Over J&J Stent Recall Reopened
- Bioethics Panel Seeks Input On Genome Privacy Issues
- Judge Approves $158M Settlement Of J&J Risperdal Suit
- Understanding Christopher V. SmithKline
- Merck Suit To Bar Ky. AG From Hiring Outside Attys Kept Alive
- Glaxo Settles Cancer Treatment IP Skirmish With Genentech
- Bill Would Allow Labeling Suits Against Generics Cos.
- Medical Device Makers Claim $20B Tax Will Hurt Jobs
- Syringe Maker Brings Claim Construction Feud To High Court
- Petition Over Prempro Injury Suits Turned Down By High Court
- AstraZeneca Can't Get FDA Tip-Off On Generic Approvals
- J&J Questions $158M Settlement Of Texas' Risperdal Suit
- Roche Again Extends $5.7B Offer To Illumina Shareholders
- FDA Considers Changes To Obesity Drug Clinical Trials
- High Court Health Reform Battle Focuses On Tax Law
- Healthpoint Stuck In $90M Medicaid Fraud Suit
- Automated Infusion Patent Claims Toothless, Fed. Circ. Finds
- Pa. High Court Rules J&J Not Liable In Surgery Death
- High Court Sends Myriad Gene Patent Row Back To Fed. Circ.
- Supreme Court Blocks Apotex Glaucoma Drug Invalidity Appeal
- Columbia Sues Illumina Over DNA Mapping Patents
- Pharmaceutical Industry Trending Toward Self-Regulation
- Biomet Inks $23M Deal In Latest Doctor Bribery Sting
- AstraZeneca Can't Prevent FDA Approval Of Generic Seroquel
- Roche Gets New Look On Timeliness Of Accutane Case
- Drug Claims Violate FCA, Ex-Pfizer Exec Tells 1st Circ.
- Tracking Foreign Direct Investment In Ireland
- Health Care Reform Faces Ultimate Test In High Court
- Zoll Shareholder Files Class Action Over $2B Asahi Sale
- Doctors Urge Over-The-Counter Birth Control At FDA Hearing
- USPTO Tells Examiners How To Apply Prometheus Ruling
- EUSA Pharma To Pay $180K Over Inflated Medicare Claims
- Merck Loses Challenge To Private Vioxx Prosecution
- Pfizer Can't Shake Fraud Suit Over Risky Arthritis Drugs
- Experts Say FDA Ignored Evidence In High-Dose Aricept Review
- False Marking Changes Unconstitutional, Group Says
- Covidien To Shell Out $108M For Ventilator Maker
- FDA Ordered To Target Antibiotics In Animal Feed
- BPA's Expiration Date May Be On Its Way
- DC Circ. Renews CVS Pharmacies' Controlled Drug Sales Ban
- Genzyme Tops Cobrek In Kidney Drug Patent Fight
- UK Court Invalidates AstraZeneca's Seroquel XR Patent
- Judge Trims Expert Testimony In Novartis Bone Drug Suit
- High Court Asked To Reinstate $26M Merck Vioxx Judgment
- More Inspiration From The Courts On Commercial Speech
- Fed. Circ. Axes Sanofi IP Claims Over Genentech Cancer Drugs
- House Votes To Nix Medicare Cost-Cutting Board
- Husch Blackwell Picks Up Duane Morris Patent Pro
- Wash. Takes Emergency Contraceptives Ruling To 9th Circ.
- Stryker's Wingspan Stent May Raise Stroke Risk, FDA Says
- Justices' Questions May Signal Health Mandate's Fate
- Pharmacies Targeted In Probe Of Gray-Market Drug Sales
- Stakeholders To Weigh In On Making More Drugs OTC
- Weil Expands Into NJ With Princeton Office
- GOP Zeroes In On Agency Implementing Health Care Law
- Judge Tosses Calif. County's Vioxx Class Action
- Fewer Life Sciences Co. Investor Suits Lodged In 2011
- DC Circ. Says ViroPharma Can't Sue FDA Over Generics Ruling
- GSK, J&J Back New $198.5M Incubator Fund
- Expanding The 'Quick Look' Framework
- Skowron To Pay Morgan Stanley $10.2M For Stock Dump
- Roche Urges Illumina Shareholders To Spur $6B Merger
- Canada Places Cancer Warnings On Merck And GSK Drugs
- Dissecting Mayo V. Prometheus
- Waxman Pressures FTC On $29B Express Scripts, Medco Deal
- Rising Star: King & Spalding's Marian Lee
- Pfizer To Pay Oregon $3.3M To End Zyvox Marketing Suit
- Foley Scores Former White House International IP Guru
- Judge Tainted $60M Trademark Row, NuVasive Tells 9th Circ.
- OTC Drugmaker Says BioZone Breached Cold Meds Contract
- Case Study: Abbott Point Of Care V. Epocal
- Prometheus Blood Test Unpatentable, High Court Rules
- GSK Asks High Court To Buck DOL On Sales Reps' OT Status
- Mylan, Apotex Secure FDA Approval For Generic Boniva
- Rising Stars: Hunton & Williams' Colleen Heisey
- FDA Recalls Brilliant Blue G After Eye Infection Reports
- Mercer Consultant Pleads Guilty To Insider Trading
- Tax Code Ruling Could Leave Health Reform Law In Limbo
- FTC Urged To Probe Merck, Sanofi Vaccine Bundling
- Judge Clears Feds For Withholding Generic Vancocin Docs
- Presenting ... A Fresh Interpretation Of Old Policy
- Covidien Shells Out $300M For Israeli Medical Device Maker
- Novartis Bone Drug Action Doomed By Statute Of Limitations
- Eisai Says Sanofi Misled Court In Feud Over Deposition Docs
- Obama Admin Floats Proposals On Contraception Rules
- Baxter Scores $24M Judgment In Fresenius Patent Suit
- DC Circ. Revives Cardinal Shipping Ban In Oxycodone Fight
- High Court Vows Same-Day Audio Of Health Care Debate
- Sens. Push For Stalled FDA Rule On Device ID System
- Genzyme Targets InvaGen Over Kidney Treatment Generics
- Jury Rules In Favor Of Carl Zeiss In Lens Patent Suit
- Synthes, Stryker Settle Trade Secrets Suit Over Sales Reps
- Case Study: Bristol-Myers V. Kappos
- Sanofi Acquires Pluromed To Commercialize Surgical Gel
- Impax Can't Shake Injunction On Generic Amrix
- Bipartisanship Breaks Down Behind Medicare Board Repeal
- GSK Strikes $613M Deal With Omega For OTC Brands, Plant
- Sanofi Asks Fed. Circ. To Upset Dr. Reddy's Allegra Patent Win
- Consultant Cops To Insider Trading On Carlyle's NBTY Buy
- CVS Caremark Says No Wrongdoing Alleged In FCA Suit
- Shire Inks $325M Deal For Blood Disorder Drug Co.
- Guidant Can't Kill $726M FCA Suit Over Implant Claims
- Biotech Co. Sues Sandoz Over Remodulin Generic
- Shire Pulls US Drug Application, Blames FDA Delay
- Albemarle Loses Bid To Toss EPA Clean Air Act Suit
- The Ever-Broadening Reach Of Dukes
- Trends In White Collar Crime Investigations, Prosecutions
- Professor Seeks FDA Probe Into Stem Cell Cos.' Practices
- Faruqi Firm Won't Get Lead Role In Roche Takeover Action
- Microsoft Revises Privacy Policy To Reflect Targeted Health Ads
- DC Circ. Lifts CVS Pharmacies' Prescription Sale Ban
- Roche Loses Bid To Block Generic Boniva
- Teva Gets FDA Green Light For 1st Lexapro Generic
- HHS Loosens Oversight Of Medicare Equipment Suppliers
- Judge Slashes Ex-Omeros Exec's FCA Suit Over NIH Grants
- Forest Labs Starts Patent Battle Over Beta-Blocker
- Pay For Delay, There For The Taking?
- The Uncertainty Of Medicaid Entitlement Enforcement
- UK Medical Journal Invokes Anti-SLAPP Law In Libel Suit
- FTC Seeks More Info From Roche On $6B Illumina Takeover
- Pfizer Won't Get To Trim BYU's Bextra-Celebrex Suit
- Boston Scientific Award Upped To $42M In Cordis Stent IP War
- Roche Unit Loses In Arbitration Over Merger Of Medical Cos.
- Precision BioSciences Expands Patent War Against Cellectis
- DC Circ. Foils Bid To Ban Mercury-Containing Vaccines
- Texas Hospital Dodges $30M FCA Suit Over Drug Supplies
- Some Warner Chilcott Birth Control May Not Work, FDA Warns
- AstraZeneca Sues FDA Over Generic Seroquel Labels
- Express Scripts, Medco Delay Deal Pending FTC Review
- Medtronic Investors Sue Over $3B Inflated Stock Buyback
- Sandoz, Others Escape Faulty Painkiller Patch Case
- China Places Strict Rules On Western Digital, Hitachi Merger
- USAA Scoops Up Stake In Real Estate Investor Square Mile
- Japanese Health Giant Snaps Up Device Maker For $2.2B
- Bayer Must Allow Cancer Generic In India, Court Rules
- FDA To Review TV Drug Ads Before Broadcast
- Calif. County Wants Claims Cut Loose From Plasma MDL
- GSK Skirts FCA Suit Over Physician Kickback Program
- J&J Unit's Stelara Infringes Abbott Patents, Judge Rules
- FTC Asks Pharm Groups How To Fix $29B Express Scripts Deal
- Why Communications Is Key To Merger And Lateral Success
- Drugmaker Bryan Corp. Sues Supplier Over Ingredient Quality
- FDA Moves To Improve Tracking Of Drug Safety Issues
- FDA Approves Third Silicone Gel Breast Implant
- Vitamin C Antitrust MDL Headed For October Trial
- FDA Rebuffs AstraZeneca's Bid To Delay Generic Seroquel
- Biotech Industry Sees Dollar Signs In Jobs Bill
- Lilly, Zydus Settle ADHD Generic Infringement Case
- Sens. Probe Role Of Rite Aid Wellness Ambassadors
- Azur, Avanir Push To Arbitrate $35M FazaClo Feud
- Health Care Is Undergoing Major Surgery In 2012
- Ex-Partner Goes After Troutman In $520M Malpractice Suit
- GSK Seeks High Court Input On IP Safe-Harbor Rule
- Latham & Watkins Reps Boston Scientific In $1.3B Deal
- Add-Ons To Drug User Fee Law Hit FDA Opposition
- Limbaugh Backlash Sparks Fight Over Concentra Name
- Chadbourne Atty Can't Stop Apartment Roof Garden
- Tackling 'Pay-For-Delay' In Calif. Supreme Court
- The Interplay Between FDA Approval And Discovery Rule
- Rebuttal: If It Ain't Broke ...
- AstraZeneca Sues Mylan Over Nexium Patents
- Judge Blocks Rival Botox Drug In Trade Secrets Trial
- Google Ordered To Dispense Canadian Pharmacy Ad Docs
- Investor Fights Illumina's Poison Pill Against Roche Bid
- Takeda Hid Diabetes Drug's Heart Risks, Ex-Reviewer Says
- Senate OKs Bill To Beef Up Counterfeit Drug Penalties
- Pfizer, Others Sued By Health Plans Over Copay Coupons
- Amgen Seeks High Court Review Of Investor Class Cert.
- Boiron To Pay Up To $12M To End False Advertising Suits
- Enzo Targets Abbott, Others Over DNA Testing Patents
- US Collected $509M FCPA Fines In 2011: Report
- GOP Lawmakers Scrutinize Low-Cost Drug Program
- 11th Circ. Limits Contribution Claims Under CERCLA
- J&J Unit In Hot Seat Over Pfizer ThermaCare IP
- Lawmakers Demand Info On Agencies' Email Monitoring Rules
- Medtronic Had Burden In Device IP Suit, Fed Circ. Told
- Reed Smith Guides Domain In $760M Venture With Rusnano
- Coventry, Policyholders Agree To $3.3M Deal Over Copays
- AeroShot Caffeine Inhaler Scrutinized By FDA
- FDA Finds Multiple Quality Violations At Synthes Plant
- Avanir Targets Watson In Suit Over Nuedexta Patents
- Premerger Plans Aren't Anti-Competitive: Calif. Court
- DC Circ. Lifts Shipping Ban On Cardinal Health
- Mensing Shields Generics Makers In Sprawling Darvocet MDL
- Immucor To Pay $22M To Stanch Blood Test Antitrust Action
- Doctors Bash Plan To Fight Rx Abuse By Denying Claims
- Zingers Fly As House Closes In On Medicare Board Repeal
- Ex-FDA Chemist Gets 5 Years For Insider Trading
- FDA Rejects Merck's Combo Cholesterol Drug For Now
- Novo Nordisk Faces $70M Sales Rep OT Action
- A Cloak Of Invisibility Is A 'Don't' In The Courtroom
- Eliminating A Standing Requirement Under Calif. UCL, FAL
- UK Biotech Co. Abcam Expands With $170M Epitomics Buy
- BP Settlement Dwarfs Top Product, Toxic Tort Deals
- DaVita Can't Escape FCA Suit Over Kidney Med Charges
- Sunovion Knocks Out 5 Patents In Mylan's Brovana Suit
- Invisalign Maker Tells ITC Rival's Imports Infringe Patents
- Millennium Labs Wants Rival's Attys Booted For Misconduct
- Merck Action Didn't Stop The Clock, Va. High Court Says
- Law360 Life Sciences Editorial Advisory Board
- Law360 Health Editorial Advisory Board
- Perkins Coie Nabs Health Team For New Practice Group
- Law360 Intellectual Property Editorial Advisory Board
- GSK Shakes EU Scrutiny In Generics Delay Probe
- How CMS Plans To Recoup Medicare, Medicaid Overpayments
- New Drug Co. Ethics Rules Focus On Doctor Relations
- Jury Sides With Pfizer Unit In Prempro Breast Cancer Case
- HHS' Sebelius Under Fire Over Contraception Rules
- FDA Warns Of 2 Hazardous Chemicals Used In Drugs
- Pfizer, Apotex End Patent Fight Over Generic Lipitor
- FDA Delays Approval Of Pfizer-BMS Anti-Clotting Drug
- Reglan Failure-To-Warn Suit Brought To Supreme Court
- Cardinal Health Painkiller Shipment Suspension Upheld
- Investor Objections Can't Halt Amgen's $1.2B Micromet Buy
- Pfizer Asks High Court To Scrap Novartis Hemophilia Patents
- EU Kills Generics Delay Probe Of AstraZeneca, Nycomed